

One-Stop Hub for all Pharmaceutical Solutions

To

NSE Scrip: VILINBIO

Sub: Cautionary e-mail received dated August 22, 2025

Ref: Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2025 ("Listing Regulations")

Dear Sir / Madam,

With regards to the cited subject, this is to inform that the Company has received a cautionary e-mail from the National Stock Exchange with respect to the delay in filing of the Board Meeting Outcome dated August 22, 2024. The copy of the e-mail received is enclosed.

The Company will place the said non-compliance in the forthcoming Board Meeting and the corrective measures taken by the Board will be intimated to the Stock Exchange.

For Vilin Bio Med Limited

Madhusudhan Yadamakanti Reddy
Director
DIN: 02874260

SPAM VILINBIO-Cautionary Email



From

To

Date

<neaps@nse.co.in>

<cs@vilinbiomed.co.in>

2025-08-22 18:10

Dear Sir/ Madam,

This is in reference to the announcement submitted by the Company on August 22, 2024, regarding the appointment of additional Independent Director of the Company.

As per Regulation 30 read with sub-para 7 of Para A Part A of Schedule III of SEBI (LODR) Regulations, 2015 read with SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023, in case of appointment of directors, key managerial personnel (Managing Director, Chief Executive Officer, Chief Financial Officer, Company Secretary etc.), senior management, Auditor and Compliance Officer shall be disclosed to the Stock Exchanges by the listed entities within 30 minutes of conclusion of the Board Meeting.

In the above case, the Exchange has observed that the aforesaid intimation was not submitted within the prescribed timelines of 30 minutes of conclusion of the Board Meeting as per sub-para 7 of Para A of Part A of Schedule III of SEBI LODR.

The aforesaid non-compliance on your part is viewed seriously. You are hereby advised to be cautious in future, exercise due diligence and initiate corrective steps to avoid recurrence of such lapses so as to ensure due compliance with the applicable provisions of SEBI LODR and related SEBI circulars. Any aberration in future will be viewed seriously and appropriate action would be initiated.

The Company is required to disseminate a copy of this Cautionary email on the Stock Exchanges where they are listed.

Additionally, the Company is advised to place before their Board of Directors this Cautionary email and the corrective measures taken by the Company to avoid recurrence of such lapses in future.

This is system generated email, you may reach out to the Announcements Team in case of any assistance at takeover@nse.co.in.